More than 1.1 million people in the UK have been diagnosed with nonvalvular atrial fibrillation (NVAF)1. A significant proportion need anticoagulation therapy to mitigate the risk of stroke and thrombo-embolic events. Due to earlier and systematic diagnosis as well as better public awareness of the condition, the number of patients diagnosed with NVAF constantly increases, resulting in capacity issues and overstretched NHS resources.
How can we improve patient care when treating NVAF and address unmet patient needs? Join our workshop at the ABPI Annual Conference to better understand how Joint Working and service redesign helped the local NHS to maximize pathway effectiveness and optimize patient access to new technologies, leading to better outcomes and an improved patient experience overall.
Quintiles hosted workshop: The redesign of anti-coagulation services to improve pathway efficiency and patient care, led by John Procter and Zoe Williams, will include a case study example and a panel discussion with representatives from Pfizer and Bayer.